Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer.

A total of 453 patients were randomized (223 participants per group) and while a statistically significant improvement in PFS was reported (4.5 versus 4.3 months, respectively; HR, 0.75; 95% CI, 0.61–0.91; p = 0.0023), median OS was 10.8 and 9.7 months (HR, 0.80; 95% CI, 0.64–0.98; p = 0.0164) ( Table 1 ), 39 and the combination failed to reach statistical significance for OS primary endpoint.

also in 6,035 other papers